Viral hepatitis amidst COVID-19 in Africa: Implications and Recommendations


Posted: 2021-09-10 19:00:00
J Med Virol . 2021 Sep 10. doi: 10.1002/jmv.27330. Online ahead of print. Affiliations Expand Affiliations 1 Dow University of Health Sciences, Karachi, Pakistan. 2 Department of Dentistry, School of Biomedical and Health Sciences, European University of Madrid, 28670, Madrid, Spain. 3 Kasturba Medical College, Manipal, India. 4 Federal University of Bahia, Salvador, Bahia, Brazil. 5 District Head Quarters Teaching Hospital, Faisalabad, Pakistan. 6 Kabul University of Medical Sciences, Kabul, Afghanistan. Item in Clipboard Syeda Kanza Kazmi et al. J Med Virol. 2021. Show details Display options Display options Format J Med Virol . 2021 Sep 10. doi: 10.1002/jmv.27330. Online ahead of print. Affiliations 1 Dow University of Health Sciences, Karachi, Pakistan. 2 Department of Dentistry, School of Biomedical and Health Sciences, European University of Madrid, 28670, Madrid, Spain. 3 Kasturba Medical College, Manipal, India. 4 Federal University of Bahia, Salvador, Bahia, Brazil. 5 District Head Quarters Teaching Hospital, Faisalabad, Pakistan. 6 Kabul University of Medical Sciences, Kabul, Afghanistan. Item in Clipboard CiteDisplay options Display options Format Abstract Hepatitis, a significant cause of mortality worldwide, results in around 1.34 million deaths each year globally. Africa is not exempt from the plague of Hepatitis. Around 100 million estimated individuals are infected with Hepatitis B (HBV) or C (HCV). Egypt has the highest prevalence cases of Hepatitis followed by Cameroon and Burundi. The continent is severly affected by the onset of the COVID-19 pandemic, as the virus has added additional burden on the already fragile continent. With the pandemic, it is presumable that Hepatitis like other viral diseases will pose a threat to collapsing healthcare system. Therefore, for Africa to become more resilient in the face of such menaces, including Hepatitis, further prevention policies are required to be implemented This article is protected by copyright. All rights reserved. Keywords: Coronavirus; Hepatitis A virus; Virus classification; Virus classification, Hepatitis B virus; Virus classification, Hepatitis C virus. This article is protected by copyright. All rights reserved. [x] Cite Copy Format: Send To [x]

参考サイト PubMed: covid-19


Powered by Vergleichsportal


バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
5月 11, 2020 バイオアソシエイツ

COVID-19治療薬レロンリマブについてのQ&A、リファレンス

2020年5月1日CytoDyn社WEBINARにおけるレロンリマブに関する質問(ログインするとQ&Aを表示):• この薬は COVID-19 の単剤治療に使用できますか?それとも最終的な分析に役立つ併用薬物療法を想定していますか?• FDAがレロンリマブを使用することで何人の命を救うことができるのかを理解するのが難しいのはなぜですか?• レロンリマブは、主に免疫系の回復または何らかの新しいメカニズムによる血漿ウイルス負荷を軽減する能力がありますか?•…